BioCardia Reports Positive Results from Heart Failure Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy BCDA?
BioCardia reported late breaking echocardiography results from its Phase III clinical trial for ischemic heart failure of reduced ejection fraction, which affects millions of patients in the United States. The clinical results were presented by Dr. Amish Raval, M.D., Professor of Medicine at University of Wisconsin School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal Investigator, in the late breaking clinical trial oral presentation session of the Technology and Heart Failure Therapeutics on behalf of the CardiAMP HF Investigators. The presentation was titled: Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF Trial. Dr. Raval reported that patients receiving the autologous CardiAMP cell therapy under investigation demonstrated positive evidence of decreased pathological left ventricular remodeling over time compared to patients not receiving the treatment. These results correlated to findings for the trial primary and key secondary endpoints of reduced fatal and non-fatal major adverse cardiovascular events and improved quality of life measures for treated patients
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCDA
Wall Street analysts forecast BCDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.160
Low
6.00
Averages
15.50
High
25.00
Current: 1.160
Low
6.00
Averages
15.50
High
25.00
No data
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCardia Reports Financials and Clinical Trial Progress
- Financial Overview: BioCardia Inc (NASDAQ:BCDA) reported a slight increase in net loss to $8.2 million for 2025, reflecting ongoing financial challenges, although cash and cash equivalents rose slightly to $2.5 million, indicating stable resource management.
- R&D Expense Growth: Research and development expenses increased by 13% to $5 million in 2025, primarily due to trial closeout activities and regulatory efforts, which could strain financial resources and impact future investment capabilities.
- Clinical Trial Progress: BioCardia has made positive strides with its CardiAM therapy for heart disease, showing statistically significant improvements in heart function with p-values of 0.02 and 0.01, indicating potential for market entry.
- Regulatory Engagement and Market Outlook: The company is actively engaging with the FDA and Japan's PMDA for potential therapy approval, and while enrollment in the HF2 trial is progressing slowly, strong data support will drive future regulatory discussions and trial recruitment.
See More
BioCardia Q4 2025 Earnings Call Insights
- Clinical Trial Data: CEO Peter Altman highlighted that BioCardia has complete data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results showing significant reductions in left ventricular volume during both diastole and systole, with p-values of 0.06 and 0.09, indicating clinically meaningful and statistically significant treatment effects.
- R&D Expense Growth: CFO David McClung reported total expenses of $8.3 million for 2025, reflecting a year-over-year increase of approximately 3%, with R&D expenses reaching $5 million, demonstrating the company's ongoing commitment to advancing therapeutic candidates.
- Cash Flow Status: BioCardia reported a net loss of $8.2 million for 2025, with approximately $7.5 million used in operations, and year-end cash and equivalents totaling $2.5 million, indicating the company's efforts to manage cash burn effectively.
- Regulatory Progress Expectations: Management anticipates soon submitting the Q-sub request for the CardiAMP system to the FDA, with a 45-day turnaround expected for feedback under breakthrough designation, which could significantly enhance the company's market access prospects.
See More
BioCardia Reports FY 2025 Financial Results with Increased Losses
- Financial Performance: BioCardia reported a FY 2025 GAAP EPS of -$1.23, missing estimates by $0.03, indicating ongoing challenges in profitability that may affect investor confidence.
- Operating Cash Flow: The net cash used in operations for FY 2025 was approximately $7.4 million, a decrease from $7.9 million in 2024, primarily due to the timing of supplier payments, reflecting an improvement in cash flow management.
- Cash Reserves: As of the end of 2025, the company had cash and cash equivalents totaling approximately $2.5 million, which, despite the cash flow improvement, raises concerns about liquidity to support future operations and growth.
- Net Loss Situation: The net loss for FY 2025 modestly increased to approximately $8.2 million compared to $7.9 million in 2024, indicating ongoing challenges in cost control and revenue enhancement that may impact long-term sustainability.
See More
BioCardia to Report Financial Results on March 24, 2026
- Earnings Call Announcement: BioCardia will provide its financial results for the year ended December 31, 2025, during a conference call on March 24, 2026, at 4:30 PM EDT, highlighting advancements in therapies for cardiovascular and pulmonary diseases.
- Participation Details: Registered participants can obtain their dial-in numbers via the provided link, while those unregistered can listen by calling 1-833-316-0559 in the U.S. or 1-412-317-5730 internationally, with a recommendation to join the call 10 minutes early for smooth access.
- Webcast and Replay Availability: The conference call will be available via live webcast, and a replay will be accessible approximately one hour after the call ends, allowing investors who cannot attend live to stay informed and enhancing corporate transparency.
- Company Overview: BioCardia focuses on developing cellular and cell-derived therapeutics for heart disease, with its CardiAMP and CardiALLO platforms utilizing Helix and Morph technologies to improve treatment outcomes for heart failure and acute myocardial infarction.
See More
BioCardia Receives FDA Pre-Submission Acceptance for Helix Catheter
- FDA Pre-Submission Acceptance: BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, marking a significant step toward potential marketing clearance and promising new treatment options in cardiac therapeutics.
- Innovative Delivery Method: The Helix catheter utilizes a small helical needle that stabilizes within the beating heart, enabling safe and precise delivery of therapeutic agents to hard-to-reach areas, thereby enhancing the efficacy of cell, gene, and protein therapies.
- Clinical Trial Progress: BioCardia's CardiAMP cell therapy is undergoing a pivotal Phase 3 trial, with an FDA Q-Sub meeting scheduled for Q1 2026 to discuss the approval pathway, a milestone that could have profound implications for the company's future growth.
- Market Performance Recovery: BCDA shares have traded between $1.00 and $3.20 over the past year, closing at $1.27 on Monday, and rising to $1.38 in pre-market trading, reflecting an 8.66% increase, indicating market optimism regarding its future prospects.
See More
BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
See More
BioCardia Reports Financials and Clinical Trial Progress
- Financial Overview: BioCardia Inc (NASDAQ:BCDA) reported a slight increase in net loss to $8.2 million for 2025, reflecting ongoing financial challenges, although cash and cash equivalents rose slightly to $2.5 million, indicating stable resource management.
- R&D Expense Growth: Research and development expenses increased by 13% to $5 million in 2025, primarily due to trial closeout activities and regulatory efforts, which could strain financial resources and impact future investment capabilities.
- Clinical Trial Progress: BioCardia has made positive strides with its CardiAM therapy for heart disease, showing statistically significant improvements in heart function with p-values of 0.02 and 0.01, indicating potential for market entry.
- Regulatory Engagement and Market Outlook: The company is actively engaging with the FDA and Japan's PMDA for potential therapy approval, and while enrollment in the HF2 trial is progressing slowly, strong data support will drive future regulatory discussions and trial recruitment.
See More
BioCardia Q4 2025 Earnings Call Insights
- Clinical Trial Data: CEO Peter Altman highlighted that BioCardia has complete data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results showing significant reductions in left ventricular volume during both diastole and systole, with p-values of 0.06 and 0.09, indicating clinically meaningful and statistically significant treatment effects.
- R&D Expense Growth: CFO David McClung reported total expenses of $8.3 million for 2025, reflecting a year-over-year increase of approximately 3%, with R&D expenses reaching $5 million, demonstrating the company's ongoing commitment to advancing therapeutic candidates.
- Cash Flow Status: BioCardia reported a net loss of $8.2 million for 2025, with approximately $7.5 million used in operations, and year-end cash and equivalents totaling $2.5 million, indicating the company's efforts to manage cash burn effectively.
- Regulatory Progress Expectations: Management anticipates soon submitting the Q-sub request for the CardiAMP system to the FDA, with a 45-day turnaround expected for feedback under breakthrough designation, which could significantly enhance the company's market access prospects.
See More
BioCardia Reports FY 2025 Financial Results with Increased Losses
- Financial Performance: BioCardia reported a FY 2025 GAAP EPS of -$1.23, missing estimates by $0.03, indicating ongoing challenges in profitability that may affect investor confidence.
- Operating Cash Flow: The net cash used in operations for FY 2025 was approximately $7.4 million, a decrease from $7.9 million in 2024, primarily due to the timing of supplier payments, reflecting an improvement in cash flow management.
- Cash Reserves: As of the end of 2025, the company had cash and cash equivalents totaling approximately $2.5 million, which, despite the cash flow improvement, raises concerns about liquidity to support future operations and growth.
- Net Loss Situation: The net loss for FY 2025 modestly increased to approximately $8.2 million compared to $7.9 million in 2024, indicating ongoing challenges in cost control and revenue enhancement that may impact long-term sustainability.
See More
BioCardia to Report Financial Results on March 24, 2026
- Earnings Call Announcement: BioCardia will provide its financial results for the year ended December 31, 2025, during a conference call on March 24, 2026, at 4:30 PM EDT, highlighting advancements in therapies for cardiovascular and pulmonary diseases.
- Participation Details: Registered participants can obtain their dial-in numbers via the provided link, while those unregistered can listen by calling 1-833-316-0559 in the U.S. or 1-412-317-5730 internationally, with a recommendation to join the call 10 minutes early for smooth access.
- Webcast and Replay Availability: The conference call will be available via live webcast, and a replay will be accessible approximately one hour after the call ends, allowing investors who cannot attend live to stay informed and enhancing corporate transparency.
- Company Overview: BioCardia focuses on developing cellular and cell-derived therapeutics for heart disease, with its CardiAMP and CardiALLO platforms utilizing Helix and Morph technologies to improve treatment outcomes for heart failure and acute myocardial infarction.
See More
BioCardia Receives FDA Pre-Submission Acceptance for Helix Catheter
- FDA Pre-Submission Acceptance: BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, marking a significant step toward potential marketing clearance and promising new treatment options in cardiac therapeutics.
- Innovative Delivery Method: The Helix catheter utilizes a small helical needle that stabilizes within the beating heart, enabling safe and precise delivery of therapeutic agents to hard-to-reach areas, thereby enhancing the efficacy of cell, gene, and protein therapies.
- Clinical Trial Progress: BioCardia's CardiAMP cell therapy is undergoing a pivotal Phase 3 trial, with an FDA Q-Sub meeting scheduled for Q1 2026 to discuss the approval pathway, a milestone that could have profound implications for the company's future growth.
- Market Performance Recovery: BCDA shares have traded between $1.00 and $3.20 over the past year, closing at $1.27 on Monday, and rising to $1.38 in pre-market trading, reflecting an 8.66% increase, indicating market optimism regarding its future prospects.
See More
BioCardia Completes FDA Pre-Submission for Helix Catheter Approval
- FDA Pre-Submission Completed: BioCardia has completed its FDA pre-submission for the Helix transendocardial delivery catheter, supported by data from 15 clinical trials demonstrating safety and efficacy in cardiac therapies, which is expected to enhance the company's market position in cardiovascular disease treatment.
- Breakthrough Designation: The pre-submission is conducted under the FDA Breakthrough Designation for the CardiAMP Cell Therapy System, with BioCardia planning to align with the FDA on the regulatory pathway within the next 45 days, potentially accelerating market entry.
- Significant Technical Advantages: The Helix catheter has demonstrated a three-fold increase in effective dosing compared to open surgical access and superior procedural safety in clinical trials, which is likely to attract more biopharmaceutical partners to utilize its innovative technology.
- Huge Market Potential: FDA approval will reduce development risks for BioCardia's therapies for heart failure and chronic myocardial ischemia, paving the way for future approvals of its autologous and allogeneic cell therapies to meet enormous unmet medical needs.
See More
